SCHEMBL24846120

SCHEMBL24846120

CCN(C[C@@H](O)C(F)(F)F)C(=O)Nc1nnc(Cc2cc(Cl)cc(Cl)c2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ XBP1 P17861 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ CYP1A2 P05177 3/20 0.39
▸ CYP2C9 P11712 3/20 0.39
▸ CYP2C19 P33261 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ SIRT2 Q8IXJ6 1/20 0.38
▸ POLB P06746 4/20 0.37
▸ RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24846681 0.94 SMN1; SMN2 (0.42) GAAL3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL24846091 0.91 SMN1; SMN2 (0.44) GAAL3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL24846671 0.89 DGAT1 (0.40) GAAALDH1A1SMN1; SMN2MAPTXBP1
SCHEMBL24846661 0.88 L3MBTL1 (0.39) L3MBTL1ALDH1A1SMN1; SMN2MAPTCYP1A2
SCHEMBL24846672 0.88 SMN1; SMN2 (0.42) L3MBTL1ALDH1A1SMN1; SMN2MAPTCYP1A2
SCHEMBL24846112 0.86 KMT2A (0.37) GAASMN1; SMN2MAPTXBP1NPSR1
SCHEMBL24846064 0.84 KMT2A (0.47) GAASMN1; SMN2MAPTXBP1NPSR1
SCHEMBL24846603 0.83 SMN1; SMN2 (0.39) L3MBTL1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL24846680 0.83 SMN1; SMN2 (0.37) GAAL3MBTL1SMN1; SMN2MAPTXBP1
SCHEMBL24846095 0.78 DGAT1 (0.42) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002336-A1 MrgprX2 Antagonists and Uses Thereof DERMIRA, INC. 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002336-A1 MrgprX2 Antagonists and Uses Thereof MRGPRX2, MRGPRX1, MRGPRX4 GAA 709/4885L3MBTL1 4659/4885ALDH1A1 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback